PetMed Express (NAS: PETS) is expected to report Q1 earnings around July 16. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict PetMed Express' revenues will expand 4.4% and EPS will increase 4.5%.
The average estimate for revenue is $76.8 million. On the bottom line, the average EPS estimate is $0.23.
Last quarter, PetMed Express logged revenue of $55.9 million. GAAP reported sales were 9.8% higher than the prior-year quarter's $50.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.20. GAAP EPS of $0.19 for Q4 were 5.6% higher than the prior-year quarter's $0.18 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 33.9%, 40 basis points worse than the prior-year quarter. Operating margin was 11.2%, 150 basis points worse than the prior-year quarter. Net margin was 7.1%, 100 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $245.9 million. The average EPS estimate is $0.78.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 866 members out of 895 rating the stock outperform, and 29 members rating it underperform. Among 222 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 212 give PetMed Express a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PetMed Express is underperform, with an average price target of $11.00.
While many retailers continue to struggle in these tough economic times, a select few are changing the face of the business and reaping outsized rewards. Is PetMed Express the right stock for you? Read "The Death of Wal-Mart: The Real Cash Kings Changing the Face of Retail" and decide. Click here for instant access to this free report.
Add PetMed Express to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.